INmune Bio
INMB
52 hedge funds and large institutions have $32.2M invested in INmune Bio in 2024 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 7 closing their positions.
1,384% more call options, than puts
Call options by funds: $653K | Put options by funds: $44K
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
55% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 11
24% more capital invested
Capital invested by funds: $26M → $32.2M (+$6.23M)
8% more funds holding
Funds holding: 48 → 52 (+4)
2.41% more ownership
Funds ownership: 12.8% → 15.21% (+2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.63M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.34M |
| 3 |
Goldman Sachs
New York
|
+$1.06M |
| 4 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$1.01M |
| 5 |
Jane Street
New York
|
+$373K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
QCG
Quadrant Capital Group
Cincinnati,
Ohio
|
-$676K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$409K |
| 3 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$274K |
| 4 |
6CM
683 Capital Management
New York
|
-$217K |
| 5 |
BlackRock
New York
|
-$215K |
INMB Hedge Fund Activity: Q1 2024 in Review
52 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q1 2024, worth a combined $32.2M — up 24% from $26M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new INMB positions and 7 closed out — a net gain of 4 holders — while 17 added to existing stakes and 11 trimmed.
The largest buyer was Millennium Management, adding an estimated $1.63M. The largest seller was Quadrant Capital Group, exiting entirely with an estimated $676K sold.
- 52 institutional investors held INmune Bio (INMB) as of Q1 2024, up from 48 in Q4 2023.
- Funds reported $32.2M of INmune Bio stock for Q1 2024, up 24% quarter-over-quarter.
- 11 funds opened new INmune Bio positions in Q1 2024 and 7 closed out, a net change of +4 holders.
- The largest INmune Bio buyer in Q1 2024 was Millennium Management, an estimated $1.63M added.
- The largest INmune Bio seller in Q1 2024 was Quadrant Capital Group, an estimated $676K sold.
Based on aggregated 13F filings for Q1 2024.